Late Breaking Clinical Trials Session

15 Apr 2024 3 p.m. 4 p.m.
Hall A
AlessiaFornoni Chairperson United States
MichelleRheault Chairperson University of MinnesotaUnited States
Add to My Schedule
Time Session
3 p.m.
3:10 p.m.
Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
3:10 p.m.
3:25 p.m.
Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas
Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
3:25 p.m.
3:35 p.m.
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
3:35 p.m.
3:45 p.m.
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
JonathanBarratt Free Communication University of Leicester, Leicester, UKUnited Kingdom
3:45 p.m.
3:55 p.m.
PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance